Entasis Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference
|Details of the presentations are below:|
|Event:||BMO 2019 Prescriptions for Success Healthcare Conference|
|Date:||Tuesday, June 25, 2019|
|Location:||The Mandarin Oriental New York|
|Time:||3:00 – 3:20 PM ET|
Additionally, Dr. Perros will hold 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their BMO representatives.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Source: Entasis Therapeutics Holdings Inc.